Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 5/20 | 0.52 |
| ▸ | ADH1A | P07327 | 5/20 | 0.52 |
| ▸ | ADH1C | P00326 | 4/20 | 0.43 |
| ▸ | ADH7 | P40394 | 2/20 | 0.43 |
| ▸ | ADH4 | P08319 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | DRD3 | P35462 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24362353 | 0.89 | ADH1B (0.48) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL1678779 | 0.77 | — | — | |
| SCHEMBL17592320 | 0.76 | ADH1B (0.54) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL17592492 | 0.76 | ADH1B (0.54) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL17592325 | 0.76 | ADH1B (0.54) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL29322931 | 0.75 | ALDH1A1 (0.33) | GAARAB9ASMN1; SMN2 | |
| SCHEMBL23945052 | 0.75 | MAPT (0.31) | — | |
| SCHEMBL17592164 | 0.74 | ADH1B (0.52) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL17592432 | 0.74 | ADH1B (0.52) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL17592165 | 0.74 | ADH1B (0.52) | ADH1BADH1AADH1CADH7ADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305859-A1 | An Anticonvulsant Compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2017-10-26 | — | — | US | claimed |
| EP-3191088-A1 | AN ANTICONVULSANT COMPOUND | Royal Holloway And Bedford New College (GB) | 2017-07-19 | — | — | EP | claimed |
| WO-2016038379-A1 | AN ANTICONVULSANT COMPOUND | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2016-03-17 | — | — | WO | claimed |
| US-10301263-B2 | Anticonvulsant compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2019-05-28 | — | — | US | disclosed |
| US-20170305859-A1 | An Anticonvulsant Compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-3191088-A1 | AN ANTICONVULSANT COMPOUND | Royal Holloway And Bedford New College (GB) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016038379-A1 | AN ANTICONVULSANT COMPOUND | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305859-A1 | An Anticonvulsant Compound | PSEN2, BACE2, APP | ADH1B 560/4885ADH1A 819/4885ADH1C 1285/4885 |
| US-10301263-B2 | Anticonvulsant compound | PSEN2, BACE2, APP | ADH1B 561/4885ADH1A 957/4885ADH1C 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.